Immatics N.V. (NASDAQ:IMTX – Get Free Report)’s stock price reached a new 52-week low on Friday. The company traded as low as $6.09 and last traded at $6.1760, with a volume of 127,355 shares traded. The stock had previously closed at $6.52.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on IMTX shares. Jefferies Financial Group set a $17.00 price target on shares of Immatics in a report on Tuesday, August 25th. Mizuho set a $21.00 price target on shares of Immatics in a research report on Thursday, October 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a report on Friday, September 18th. Stifel Nicolaus began coverage on Immatics in a research report on Tuesday, October 13th. They set a “buy” rating and a $15.00 target price on the stock. Finally, Wall Street Zen cut Immatics from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Immatics presently has an average rating of “Moderate Buy” and an average target price of $19.00.
Check Out Our Latest Stock Analysis on Immatics
Immatics Price Performance
Immatics (NASDAQ:IMTX – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.07). The company had revenue of $7.84 million during the quarter, compared to analysts’ expectations of $12.18 million. Immatics had a negative net margin of 533.26% and a negative return on equity of 52.54%. Equities research analysts forecast that Immatics N.V. will post -1.96 EPS for the current year.
Insiders Place Their Bets
In other news, Director Perceptive Advisors Llc bought 863,060 shares of Immatics stock in a transaction on Wednesday, August 26th. The shares were bought at an average cost of $8.69 per share, for a total transaction of $7,499,991.40. Following the acquisition, the director owned 11,246,516 shares in the company, valued at approximately $97,732,224.04. This trade represents a 8.31% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 3.30% of the company’s stock.
Institutional Investors Weigh In On Immatics
A number of hedge funds and other institutional investors have recently modified their holdings of IMTX. Aberdeen Group plc boosted its stake in shares of Immatics by 89.0% during the 3rd quarter. Aberdeen Group plc now owns 1,235,460 shares of the company’s stock valued at $10,847,000 after buying an additional 581,856 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Immatics in the third quarter worth $3,685,000. Troluce Capital Advisors LLC bought a new stake in shares of Immatics in the first quarter worth $2,460,000. Wellington Management Group LLP increased its stake in shares of Immatics by 5.5% in the second quarter. Wellington Management Group LLP now owns 1,647,852 shares of the company’s stock worth $16,693,000 after buying an additional 85,960 shares during the last quarter. Finally, Alps Advisors Inc. raised its holdings in Immatics by 46.2% in the third quarter. Alps Advisors Inc. now owns 198,239 shares of the company’s stock valued at $1,741,000 after acquiring an additional 62,640 shares in the last quarter. 64.41% of the stock is currently owned by hedge funds and other institutional investors.
Immatics Company Profile
Immatics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Founded in Germany in 2000, the company uses its target-discovery and development platforms to identify cancer-associated targets and create therapies designed to direct the immune system against tumor cells. Its pipeline includes engineered T-cell receptor (TCR) T-cell therapies, which modify a patient’s T cells to recognize specific tumor targets, as well as TCR bispecific therapies designed to connect T cells with cancer cells.
Featured Articles
- Five stocks we like better than Immatics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
